

Carol D Weiss

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7164460/publications.pdf>

Version: 2024-02-01

42
papers

2,022
citations

331670

21
h-index

254184

43
g-index

44
all docs

44
docs citations

44
times ranked

2021
citing authors

#	ARTICLE	IF	CITATIONS
1	Capture of an early fusion-active conformation of HIV-1 gp41. <i>Nature Structural Biology</i> , 1998, 5, 276-279.	9.7	482
2	Peptides Trap the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Fusion Intermediate at Two Sites. <i>Journal of Virology</i> , 2003, 77, 1666-1671.	3.4	134
3	Thiol/disulfide exchange is a prerequisite for CXCR4-tropic HIV-1 envelope-mediated T-cell fusion during viral entry. <i>Blood</i> , 2004, 103, 1586-1594.	1.4	129
4	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	27.8	117
5	Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates. <i>Journal of Virology</i> , 2002, 76, 6780-6790.	3.4	115
6	Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2. <i>PLoS ONE</i> , 2021, 16, e0248348.	2.5	102
7	Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. <i>Journal of Virological Methods</i> , 2008, 153, 111-119.	2.1	94
8	Binding of the 2F5 Monoclonal Antibody to Native and Fusion-Intermediate Forms of Human Immunodeficiency Virus Type 1 gp41: Implications for Fusion-Inducing Conformational Changes. <i>Journal of Virology</i> , 2004, 78, 2627-2631.	3.4	87
9	SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies. <i>Science Translational Medicine</i> , 2022, 14, eabn8543.	12.4	75
10	Peptides Corresponding to the Heptad Repeat Motifs in the Transmembrane Protein (gp41) of Human Immunodeficiency Virus Type 1 Elicit Antibodies to Receptor-Activated Conformations of the Envelope Glycoprotein. <i>Journal of Virology</i> , 2001, 75, 8859-8863.	3.4	56
11	Influenza Virus M2 Protein Ion Channel Activity Helps To Maintain Pandemic 2009 H1N1 Virus Hemagglutinin Fusion Competence during Transport to the Cell Surface. <i>Journal of Virology</i> , 2015, 89, 1975-1985.	3.4	42
12	Structure-Function Studies of the Self-Assembly Domain of the Human Immunodeficiency Virus Type 1 Transmembrane Protein gp41. <i>Journal of Virology</i> , 2000, 74, 5368-5372.	3.4	39
13	Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. <i>Journal of Virological Methods</i> , 2010, 165, 305-310.	2.1	38
14	Cross-Neutralizing Antibodies to Pandemic 2009 H1N1 and Recent Seasonal H1N1 Influenza A Strains Influenced by a Mutation in Hemagglutinin Subunit 2. <i>PLoS Pathogens</i> , 2011, 7, e1002081.	4.7	37
15	Studies of HIV-1 envelope glycoprotein-mediated fusion using a simple fluorescence assay. <i>Aids</i> , 1996, 10, 241-246.	2.2	33
16	Antibodies to Antigenic Site A of Influenza H7 Hemagglutinin Provide Protection against H7N9 Challenge. <i>PLoS ONE</i> , 2015, 10, e0117108.	2.5	32
17	Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors. <i>Viruses</i> , 2012, 4, 3859-3911.	3.3	31
18	Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects. <i>Journal of Virology</i> , 2022, 96, JVI0111021.	3.4	29

#	ARTICLE	IF	CITATIONS
19	Human Immunodeficiency Virus (HIV) gp41 Escape Mutants: Cross-Resistance to Peptide Inhibitors of HIV Fusion and Altered Receptor Activation of gp120. <i>Journal of Virology</i> , 2005, 79, 4774-4781.	3.4	26
20	Antibodies to the A27 Protein of Vaccinia Virus Neutralize and Protect against Infection but Represent a Minor Component of Dryvax Vaccine-Induced Immunity. <i>Journal of Infectious Diseases</i> , 2007, 196, 1026-1032.	4.0	26
21	Neutralizing Antibodies Targeting the Conserved Stem Region of Influenza Hemagglutinin. <i>Vaccines</i> , 2020, 8, 382.	4.4	25
22	Intermonomer Interactions in Hemagglutinin Subunits HA1 and HA2 Affecting Hemagglutinin Stability and Influenza Virus Infectivity. <i>Journal of Virology</i> , 2015, 89, 10602-10611.	3.4	23
23	SARS-CoV-2 Delta Variant Displays Moderate Resistance to Neutralizing Antibodies and Spike Protein Properties of Higher Soluble ACE2 Sensitivity, Enhanced Cleavage and Fusogenic Activity. <i>Viruses</i> , 2021, 13, 2485.	3.3	23
24	Neutralizing and Neuraminidase Antibodies Correlate With Protection Against Influenza During a Late Season A/H3N2 Outbreak Among Unvaccinated Military Recruits. <i>Clinical Infectious Diseases</i> , 2020, 71, 3096-3102.	5.8	22
25	Selection with a Peptide Fusion Inhibitor Corresponding to the First Heptad Repeat of HIV-1 gp41 Identifies Two Genetic Pathways Conferring Cross-Resistance to Peptide Fusion Inhibitors Corresponding to the First and Second Heptad Repeats (HR1 and HR2) of gp41. <i>Journal of Virology</i> , 2011, 85, 12929-12938.	3.4	21
26	Trimeric, Coiled-coil Extension on Peptide Fusion Inhibitor of HIV-1 Influences Selection of Resistance Pathways. <i>Journal of Biological Chemistry</i> , 2012, 287, 8297-8309.	3.4	21
27	A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. <i>Virology</i> , 2010, 407, 374-380.	2.4	20
28	HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120. <i>Journal of Virology</i> , 2018, 92, .	3.4	18
29	Neutralizing and protective epitopes of the 2009 pandemic influenza H1N1 hemagglutinin. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 480-490.	3.4	16
30	Determination of influenza B identity and potency in quadrivalent inactivated influenza vaccines using lineage-specific monoclonal antibodies. <i>PLoS ONE</i> , 2017, 12, e0175733.	2.5	15
31	Glycosylation of Residue 141 of Subtype H7 Influenza A Hemagglutinin (HA) Affects HA-Pseudovirus Infectivity and Sensitivity to Site A Neutralizing Antibodies. <i>PLoS ONE</i> , 2016, 11, e0149149.	2.5	14
32	Resistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics. <i>Retrovirology</i> , 2014, 11, 86.	2.0	13
33	Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it. <i>PLoS ONE</i> , 2019, 14, e0222436.	2.5	11
34	Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018-2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin. <i>Clinical Infectious Diseases</i> , 2021, 73, e4312-e4320.	5.8	11
35	Conformational Stability of the Hemagglutinin of H5N1 Influenza A Viruses Influences Susceptibility to Broadly Neutralizing Stem Antibodies. <i>Journal of Virology</i> , 2018, 92, .	3.4	10
36	Immunogens Modeling a Fusion-Intermediate Conformation of gp41 Elicit Antibodies to the Membrane Proximal External Region of the HIV Envelope Glycoprotein. <i>PLoS ONE</i> , 2015, 10, e0128562.	2.5	9

#	ARTICLE	IF	CITATIONS
37	Serum Samples From Middle-aged Adults Vaccinated Annually with Seasonal Influenza Vaccines Cross-neutralize Some Potential Pandemic Influenza Viruses. <i>Journal of Infectious Diseases</i> , 2016, 213, 403-406.	4.0	6
38	Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 Pandemic. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx023.	0.9	6
39	Neutralizing Antibody Responses to Homologous and Heterologous H1 and H3 Influenza A Strains After Vaccination With Inactivated Trivalent Influenza Vaccine Vary With Age and Prior-year Vaccination. <i>Clinical Infectious Diseases</i> , 2019, 68, 2067-2078.	5.8	5
40	Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses. <i>Journal of Virology</i> , 2019, 93, .	3.4	2
41	Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge. <i>Vaccine</i> , 2010, 28, 699-706.	3.8	1
42	NIAID recommendations for treating HIV infection. <i>JAMA - Journal of the American Medical Association</i> , 1994, 271, 1830-1830.	7.4	0